



IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of: **YAMADA, Yoshiji, et al.**

Group Art Unit: **3762**

Serial No.: **10/517,605**

Examiner: **Not Yet Assigned**

Filed: **December 21, 2004**

P.T.O. Confirmation No.: **1240**

For: **METHOD OF DIAGNOSING RISK OF MYOCARDIAL INFARCTION**

**INFORMATION DISCLOSURE STATEMENT**  
**PURSUANT TO 37 CFR 1.97(b)**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

November 1, 2005

Sir:

The attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached Form PTO-1449. One copy of each of these documents is attached.

No fee or certification is required in connection with this Information Disclosure Statement, since it is being submitted prior to the issuance of a first official action on the merits or expiration of the three month period following the filing date or the entry of the national stage of the above-captioned application.

The above information is presented so that the Patent and Trademark Office can, in the first instance, determine any materiality thereof to the claimed invention. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the documents cited in the attached Form PTO-1449 be made of record therein and appear on the first page of any patent to issue therefrom.

The Commissioner is authorized to charge our Deposit Account No. 01-2340 for any fee which is deemed by the Patent and Trademark Office to be required to effect consideration of this statement.

Respectfully submitted,

ARMSTRONG, KRATZ, QUINTOS,  
ANSON & BROOKS, LLP

*James E. Armstrong, IV*  
James E. Armstrong, IV

Attorney for Applicants

Reg. No. 42,266

JAM/rk

Atty. Docket No. **040677**

Suite 1000

1725 K Street, N.W.

Washington, D.C. 20006

(202) 659-2930




23850

PATENT TRADEMARK OFFICE

Enclosures: PTO-1449 and references (6)



<b>INFORMATION DISCLOSURE CITATION</b> PTO-1449	Atty. Docket No. <b>040677</b>	Serial No. <b>10/517,605</b>
	Applicant(s): <b>YAMADA, Yoshiji, et al.</b>	
	Filing Date: <b>December 21, 2004</b>	Group Art Unit: <b>3762</b>



### U.S. PATENT DOCUMENTS

Examiner Initial	Document No.	Name	Date	Class	Subclass	Filing Date (If appropriate)
_____	AA					
_____	AB					

### FOREIGN PATENT DOCUMENTS

Document No.	Date	Country	Translation (Yes or No)
_____	AC		
_____	AD		

### OTHER DOCUMENTS

_____	AE	A copy of the European Patent Office Communication (including Supplementary Partial European Search Report) for corresponding European patent application No. 03712817(PCT/JP0303477), dated October 13, 2005.		
_____	AF	Hung-I. Yeh, et al. "Connexin37 gene polymorphism and coronary artery disease in Taiwan;" <i>International Journal of Cardiology</i> ; Vol. 81, pp.251-255 (2001).		
_____	AG	Werner Koch, et al. "Interleukin-10 and tumor necrosis factor gene polymorphisms and risk of coronary artery disease and myocardial infarction;" <i>Atherosclerosis</i> ; Vol. 159, pp.137-144 (2001).		
_____	AH	M. Boerma, et al. "A genetic polymorphism in connexin 37 as a prognostic marker for atherosclerotic plaque development;" <i>Journal of Internal Medicine</i> ; Vol. 246, pp.211-218 (1999).		
_____	AI	Elvis Brscic, et al. "Acute myocardial infarction in young adults: Prognostic role of angiotensin-converting enzyme, angiotensin II type I receptor, apolipoprotein E, endothelial constitutive nitric oxide synthase, and glycoprotein IIIa genetic polymorphisms at medium-term follow-up;" <i>American Heart Journal</i> ; Vol. 139, No.6, pp.979-984 (2000).		
_____	AJ	Juliano C. Padovani, et al. "Gene Polymorphisms in the TNF Locus and the Risk of Myocardial Infarction;" <i>Thrombosis Research</i> ; Vol.100, pp.263-269 (2000).		
<table border="1" style="width:100%"> <tr> <td>Examiner</td> <td>Date Considered</td> </tr> </table>			Examiner	Date Considered
Examiner	Date Considered			